Unknown

Dataset Information

0

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications.


ABSTRACT: Gene therapy to achieve in vivo secretion of recombinant anti-CD3 x anti-tumor bispecific antibodies in cancer patients is being explored as a strategy to counterbalance rapid renal elimination, thereby sustaining levels of bispecific antibodies in the therapeutic range. Here, we performed a comparative analysis between single- and two-chain configurations for anti-CD3 x anti-CEA (carcinoembryonic antigen) bispecific antibodies secreted by genetically-modified human cells. We demonstrate that tandem single-chain variable fragment (scFv) antibodies and two-chain diabodies are expressed as soluble secreted proteins with similar yields. However, we found significant differences in their biological functionality (i.e., antigen binding) and in their ability to induce non-specific T cell activation. Whereas single-chain tandem scFvs induced human T cell activation and proliferation in an antigen-independent manner, secreted two-chain diabodies exerted almost no proliferative stimulus when human T cells were cultured alone or in co-cultures with CEA negative cells. Thus, our data suggest that two-chain diabodies are preferable to single-chain tandem scFvs for immunotherapeutic strategies comprising in vivo secretion of bispecific antibodies aiming to recruit and activate anticancer specific lymphocytic effector T cells.

SUBMITTER: Compte M 

PROVIDER: S-EPMC4091452 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications.

Compte Marta M   Alvarez-Cienfuegos Ana A   Nuñez-Prado Natalia N   Sainz-Pastor Noelia N   Blanco-Toribio Ana A   Pescador Nuria N   Sanz Laura L   Alvarez-Vallina Luis L  

Oncoimmunology 20140523


Gene therapy to achieve in vivo secretion of recombinant anti-CD3 x anti-tumor bispecific antibodies in cancer patients is being explored as a strategy to counterbalance rapid renal elimination, thereby sustaining levels of bispecific antibodies in the therapeutic range. Here, we performed a comparative analysis between single- and two-chain configurations for anti-CD3 x anti-CEA (carcinoembryonic antigen) bispecific antibodies secreted by genetically-modified human cells. We demonstrate that ta  ...[more]

Similar Datasets

| S-EPMC5626922 | biostudies-literature
| S-EPMC6463744 | biostudies-literature
| S-EPMC5688922 | biostudies-literature
| S-EPMC5944627 | biostudies-literature
| S-EPMC5933537 | biostudies-literature
| S-EPMC4687327 | biostudies-literature
| S-EPMC7012161 | biostudies-literature
| S-EPMC6168351 | biostudies-literature
| S-EPMC7775505 | biostudies-literature